Multiple states have raised the alarm in the past month about cychlorphine, a synthetic opioid tied to several dozen recent ...
The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors ...
The Daily Pour on MSN
Q&A: Meet David Nutt, the Professor Who Ranked Every Drug by Societal Harm — and Put Alcohol First
Named by the Evening Standard as one of the top 100 people shaping London in 2025, Professor David Nutt has authored over 500 research papers and more than 30 books. One of the world’s foremost ...
Marseille, France, March 10, 2026 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors facilitating the targeted delivery of therapeutic molecules and ...
Solvonis Therapeutics PLC (LSE:SVNS, FRA:J4I), an emerging biopharmaceutical company focused on central nervous system disorders, has selected SVN-114 as the lead candidate from its proprietary ...
A heady combination of influencers, deregulation, GLP-1 success stories and DIY medicine are driving the phenomenal growth in ...
Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical lifespan. What it often takes to achieve that level of longevity, however, is ...
Morning Overview on MSN
Repurposed drug cut sleep apnea events by up to 50% in trial
A repurposed epilepsy drug called sultiame cut breathing interruptions during sleep by up to 50% in adults with moderate-to-severe obstructive sleep apnea, according to results from a major European ...
Managing complex medical conditions often requires the simultaneous use of multiple different drugs, referred to as polypharmacy. While necessary, this significantly increases the risk of drug-drug ...
When considering the drugs most likely to cause former addicts to repeatedly relapse, opioids, cocaine, and methamphetamine ...
A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease. Unlike ...
GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results